Antibronchoconstrictor activity of two new phosphodiesterase inhibitors, a triazolopyrazine (ICI 58 301) and a triazolopyrimidine (ICI 63 197).
D000081:Acetamides / Q000494:pharmacology; D000109:Acetylcholine / Q000037:antagonists & inhibitors; D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D001980:Bronchi / Q000187:drug effects*; D001986:Bronchial Spasm / Q000517:prevention & control; D000242:Cyclic AMP; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008168:Lung / Q000187:drug effects; D008297:Male; D010477:Perfusion; D010726:Phosphodiesterase Inhibitors; D011217:Practolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D000081:Acetamides; D006634:Histamine H1 Antagonists; D010726:Phosphodiesterase Inhibitors; D011719:Pyrazines; D011743:Pyrimidines; D011433:Propranolol; D000242:Cyclic AMP; D007545:Isoproterenol; D000109:Acetylcholine; D000420:Albuterol; D011217:Practolol; D004837:Epinephrine